• 1
    Echchakir H, Vergnon I, Dorothée G, Grunenwald D, Chouaib S, Mami-Chouaib F. Evidence for in situ expansion of diverse antitumor specific cytotoxic T lymphocyte clones in a human large cell carcinoma of the lung. Int Immunol 2000; 12: 53746.
  • 2
    Salcedo TW, Azzoni L, Wolf SF, Perussia B. Modulation of perforin and granzyme messenger RNA expression in human natural killer cells. J Immunol 1993; 151: 251120.
  • 3
    Chouaib S, Chehimi J, Bani L, Genetet N, Tursz T, Gay F, et al. Interleukin 12 induces the differentiation of major histocompatibility complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors. Proc Natl Acad Sci USA 1994; 91: 1265963.
  • 4
    Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997; 18: 4937.
  • 5
    Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes [review]. Blood 1994; 84: 400827.
  • 6
    Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998; 70: 83243.
  • 7
    Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, et al. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J Exp Med 1993; 178: 122330.
  • 8
    Rakhmilevich AL, Turner J, Ford MJ, McCabe D, Sun WH, Sondel PM, et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 1996; 93: 62916.
  • 9
    Watanabe M, McCormick KL, Volker K, Ortaldo JR, Wigginton JM, Brunda MJ, et al. Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis. Am J Pathol 1997; 150: 186980.
  • 10
    Asselin-Paturel C, Lassau N, Guinebretière JM, Zhang J, Gay F, Bex F, et al. The in vivo murine interleukin-12 transfer by the Semliki Forest Virus induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. Gene Ther 1999; 6: 60615.
  • 11
    Kurzawa H, Wysocka M, Aruga E, Chang AE, Trinchieri G, Lee WM. Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression. Cancer Res 1998; 58: 4919.
  • 12
    Koblish HK, Hunter CA, Wysocka M, Trinchieri G, Lee WM. Immune suppression by recombinant interleukin (rIL)-12 involves interferon gamma induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect. J Exp Med 1998; 188: 160310.
  • 13
    Asselin-Paturel C, Echchakir H, Carayol G, Gay F, Opolon P, Grunenwald D, et al. Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int J Cancer 1998; 77: 712.
  • 14
    Tsung K, Meko JB, Peplinski GR, Tsung YL, Norton JA. IL-12 induces T helper 1-directed antitumor response. J Immunol 1997; 158: 335965.
  • 15
    Seki S, Hashimoto W, Ogasawara K, Satoh M, Watanabe H, Habu Y, et al. Antimetastatic effect of NK1+ T cells on experimental haematogenous tumour metastases in the liver and lungs of mice. Immunology 1997; 92: 5616.
  • 16
    Salgame P, Abrams JS, Clayberger C, Goldstein H, Convit J, Modlin RL, et al. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 1991; 254: 27982.
  • 17
    Sad S, Marcotte R, Mosmann TR. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity 1995; 2: 2719.
  • 18
    Hagenbaugh A, Sharma S, Dubinett SM, Wei SHY, Aranda R, Cheroutre H, et al. Altered immune responses in interleukin 10 transgenic mice. J Exp Med 1997; 185: 210110.
  • 19
    Windhagen A, Anderson DE, Carrizosa A, Williams RE, Hafler DA. IL-12 induces human T cells secreting IL-10 with IFN-gamma. J Immunol 1996; 157: 112731.
  • 20
    de Waal Malefyt R, Yssel H, Roncarolo MG, Spits H, de Vries JE. Interleukin-10. Curr Opin Immunol 1992; 4: 31420.
  • 21
    Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, Nickoloff BJ, et al. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol 1995;155: 22407.
  • 22
    Matsuda M, Salazar F, Petersson M, Masucci G, Hansson J, Pisa P, et al. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 1994; 180: 23716.
  • 23
    Salazar-Onfray F, Charo J, Petersson M, Freland S, Noffz G, Qin Z, et al. Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. J Immunol 1997; 159: 3195202.
  • 24
    Nagy N, Vanky F. Transforming growth factor beta, (TGFbeta) secreted by immunogenic ex vivo human carcinoma cells, counteracts the activation and inhibits the function of autologous cytotoxic lymphocytes. Pretreatment with interferon gamma and tumor necrosis factor alpha reduces the production of active TGFbeta. Cancer Immunol Immunother 1998;45: 30612.
  • 25
    Todd RF III, Meuer SC, Romain PL, Schlossman SF. A monoclonal antibody that blocks class II histocompatibility-related immune interactions. Hum Immunol 1984; 10: 2340.
  • 26
    Thitheradge MA. Measurement of nitrate and nitrite. In: ThitheradgeMA, editor. Nitric Oxid Protocols. vol. 100. Totowa, NJ: Humana Press Inc, 1998: 8391.